Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Last updated: July 17, 2014
Sponsor: Massachusetts General Hospital
Overall Status: Completed

Phase

3

Condition

Depression

Depression (Adult And Geriatric)

Depression (Major/severe)

Treatment

N/A

Clinical Study ID

NCT00361374
2005P002337
5R01MH074085
  • Ages 18-80
  • All Genders

Study Summary

This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It is believed that a deficiency in these omega-3 fatty acids may lead to the development of major depression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men or women aged 18-80 years old.

  • Must meet criteria for current Major Depressive Disorder.

Exclusion

Exclusion Criteria:

  • Serious or unstable medical illness including cardiovascular, hepatic, renal,respiratory, endocrine, neurologic, or hematologic disease

  • History of seizure disorder.

  • Substance use disorders, including alcohol, active within the last six months (pasthistory is OK).

  • History of multiple adverse drug reactions or allergy to the study drugs.

Study Design

Total Participants: 196
Study Start date:
July 01, 2006
Estimated Completion Date:
March 31, 2013

Study Description

The study lasts for eight weeks and involves four visits after the screen and baseline visits (biweekly). Participants will be randomized, or chosen by chance, to enter into one of three groups. People in the first group will take 1 g/day or EPA omega-3 fatty acid, those in the second group will take 1 g/day of DHA omega-3 fatty acid, and those in the third group will take a placebo. This study is double-blind, which means that neither the participant, nor the doctor, nor the research staff will know which group each person is in. At the end of the study the participant will be offered three months of follow-up care at the Depression Clinical and Research Program.

Connect with a study center

  • Depression Clinical Research Program, Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.